Incidental detection of elastofibroma dorsi on PET-CT: initial findings and changes in tumor size and standardized uptake value on serial scans

Nucl Med Commun. 2016 Aug;37(8):837-42. doi: 10.1097/MNM.0000000000000517.

Abstract

Objective: We describe changes in elastofibroma dorsi (EFD) as observed in serial fluorine-18 fluorodeoxyglucose (F-FDG) PET-computed tomography (CT) imaging studies.

Materials and methods: F-FDG PET-CT studies carried out between January 2006 and January 2015 at a single institution were reviewed by an experienced radiologist and nuclear medicine specialist. When available, previous or subsequent imaging studies were reviewed to evaluate changes in EFD.

Results: Of 28 500 PET-CT studies carried out, EFD was identified in 68 from 20 patients (mean age 67.1±10.2 years; 14 women). Five patients had unilateral lesions and 15 patients had bilateral lesions. Eighteen patients had oncologic diseases. The mean size of EFD at first presentation was 13.95±5.90 mm and the mean homogeneous low-grade F-FDG uptake was maximum standardized uptake value (SUVmax) 2.24±0.95. One or more additional CT scans were performed in 17 patients; the mean interval between the first and last scans was 57.4±39.2 months. EFD was unchanged in size in 7/17 (41%) and showed slow growth in 10/17, reaching a mean size of 19 mm. The mean monthly growth rate was 0.1±0.10 mm. PET imaging in 11 patients showed a mean first SUVmax of 2.08±1.17 and a mean last SUVmax of 2.74±1.05 after a mean of 47.5±31.5 months (P=0.63).

Conclusion: Serial PET-CT studies may show a stable or slowly enlarging mass on a CT scan without changes in F-FDG uptake on PET imaging. Familiarity with CT appearances and F-FDG uptake of EFD are important for correct interpretation of F-FDG PET-CT studies.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Fluorodeoxyglucose F18 / pharmacokinetics*
  • Humans
  • Incidental Findings*
  • Male
  • Positron Emission Tomography Computed Tomography / methods*
  • Radiopharmaceuticals / pharmacokinetics
  • Reproducibility of Results
  • Scapula / diagnostic imaging
  • Scapula / metabolism
  • Sensitivity and Specificity
  • Soft Tissue Neoplasms / diagnosis*
  • Soft Tissue Neoplasms / metabolism*
  • Tumor Burden

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18